<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
<channel>
<title>Atara Biotherapeutics Inc — News on 6ix</title>
<link>https://6ix.com/company/atara-biotherapeutics-inc</link>
<description>Latest news and press releases for Atara Biotherapeutics Inc on 6ix.</description>
<language>en-us</language>
<lastBuildDate>Mon, 16 Mar 2026 20:05:00 GMT</lastBuildDate>
<generator>6ix RSS</generator>
<atom:link href="https://6ix.com/rss/company/atara-biotherapeutics-inc" rel="self" type="application/rss+xml" />
<image>
<url>https://6ix-events-pro.s3.amazonaws.com/6ixvideo/logos/org-logo6835496e78dffbe2df0e4409.webp</url>
<title>Atara Biotherapeutics Inc</title>
<link>https://6ix.com/company/atara-biotherapeutics-inc</link>
</image>
<item>
<title>Atara Biotherapeutics Announces Fourth Quarter and Full Year 2025 Financial Results and Operational Progress</title>
<link>https://6ix.com/company/atara-biotherapeutics-inc/news/atara-biotherapeutics-announces-fourth-quarter-and-full-year-2025-financial-results-and-operational-progress</link>
<guid isPermaLink="true">https://6ix.com/company/atara-biotherapeutics-inc/news/atara-biotherapeutics-announces-fourth-quarter-and-full-year-2025-financial-results-and-operational-progress</guid>
<pubDate>Mon, 16 Mar 2026 20:05:00 GMT</pubDate>
<description>THOUSAND OAKS, Calif., March 16, 2026--Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, today reported financial results for the fourth quarter and full year 2025 and business updates.</description>
</item>
<item>
<title>Atara Biotherapeutics Provides Regulatory Update on Tabelecleucel</title>
<link>https://6ix.com/company/atara-biotherapeutics-inc/news/atara-biotherapeutics-provides-regulatory-update-on-tabelecleucel</link>
<guid isPermaLink="true">https://6ix.com/company/atara-biotherapeutics-inc/news/atara-biotherapeutics-provides-regulatory-update-on-tabelecleucel</guid>
<pubDate>Tue, 03 Mar 2026 13:05:00 GMT</pubDate>
<description>THOUSAND OAKS, Calif., March 03, 2026--Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, today announced that its partner Pierre Fabre Pharmaceuticals (PFP) has submitted a request to the FDA for a Type A meeting.</description>
</item>
<item>
<title>Atara Biotherapeutics Provides a Business Update</title>
<link>https://6ix.com/company/atara-biotherapeutics-inc/news/atara-biotherapeutics-provides-a-business-update</link>
<guid isPermaLink="true">https://6ix.com/company/atara-biotherapeutics-inc/news/atara-biotherapeutics-provides-a-business-update</guid>
<pubDate>Mon, 23 Feb 2026 13:00:00 GMT</pubDate>
<description>THOUSAND OAKS, Calif., February 23, 2026--Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, today announced that the Company entered into an amendment (the Amendment) to the Purchase and Sale Agreement dated as of December 20, 2022 with a fund managed by HealthCare Royalty ("HCRx"). Under the terms of the Amendm</description>
</item>
<item>
<title>Atara Biotherapeutics Provides Regulatory and Business Update on EBVALLO™ (tabelecleucel)</title>
<link>https://6ix.com/company/atara-biotherapeutics-inc/news/atara-biotherapeutics-provides-regulatory-business-130000978</link>
<guid isPermaLink="true">https://6ix.com/company/atara-biotherapeutics-inc/news/atara-biotherapeutics-provides-regulatory-business-130000978</guid>
<pubDate>Mon, 12 Jan 2026 13:00:00 GMT</pubDate>
<description>THOUSAND OAKS, Calif., January 12, 2026--Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, today announced that the U.S. Food and Drug Administration (FDA) has issued a Complete Response Letter (CRL) for the EBVALLO™ (tabelecleucel) Biologics License Application (BLA) as monotherapy treatment for adult and pedia</description>
</item>
<item>
<title>Atara Biotherapeutics Announces Third Quarter Financial Results and Operational Progress</title>
<link>https://6ix.com/company/atara-biotherapeutics-inc/news/atara-biotherapeutics-announces-third-quarter-140000951</link>
<guid isPermaLink="true">https://6ix.com/company/atara-biotherapeutics-inc/news/atara-biotherapeutics-announces-third-quarter-140000951</guid>
<pubDate>Wed, 12 Nov 2025 14:00:00 GMT</pubDate>
<description>THOUSAND OAKS, Calif., November 12, 2025--Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, today reported financial results for the third quarter 2025 and business updates.</description>
</item>
<item>
<title>Pierre Fabre Pharmaceuticals Announces Transfer from Atara Biotherapeutics of the Biologics License Application (BLA) for Tabelecleucel as Treatment of Epstein-Barr Virus Positive Post-Transplant Lymphoproliferative Disease (EBV+ PTLD)</title>
<link>https://6ix.com/company/atara-biotherapeutics-inc/news/pierre-fabre-pharmaceuticals-announces-transfer-from-atara-biotherapeutics-of-the-biologics-license-application-bla-for-tabelecleucel-as-treatment-of-epstein-barr-virus-positive-post-transplant-lymphoproliferative-disease-ebv-ptld</link>
<guid isPermaLink="true">https://6ix.com/company/atara-biotherapeutics-inc/news/pierre-fabre-pharmaceuticals-announces-transfer-from-atara-biotherapeutics-of-the-biologics-license-application-bla-for-tabelecleucel-as-treatment-of-epstein-barr-virus-positive-post-transplant-lymphoproliferative-disease-ebv-ptld</guid>
<pubDate>Mon, 03 Nov 2025 14:00:00 GMT</pubDate>
<description>Pierre Fabre Pharmaceuticals Inc. (PFP) announces the transfer of the Biologics License Application (BLA) for tabelecleucel from Atara Biotherapeutics Inc. (Nasdaq: ATRA) with PFP now accountable for all aspects of the submission. Atara will continue to observe the regulatory process and provide support to PFP as needed. The tabelecleucel BLA has an FDA PDUFA target action date of January 10, 2026. If approved, the tabelecleucel will be indicated as monotherapy for treatment of adult and pediatr</description>
</item>
<item>
<title>Atara Biotherapeutics Announces Changes to Its Board of Directors</title>
<link>https://6ix.com/company/atara-biotherapeutics-inc/news/atara-biotherapeutics-announces-changes-board-220000765</link>
<guid isPermaLink="true">https://6ix.com/company/atara-biotherapeutics-inc/news/atara-biotherapeutics-announces-changes-board-220000765</guid>
<pubDate>Wed, 03 Sep 2025 22:00:00 GMT</pubDate>
<description>THOUSAND OAKS, Calif, September 03, 2025--Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, today announced that Greg Ciongoli will assume the role of Chair of the Board of Directors.</description>
</item>
<item>
<title>Atara Biotherapeutics Announces Second Quarter Financial Results and Operational Progress</title>
<link>https://6ix.com/company/atara-biotherapeutics-inc/news/atara-biotherapeutics-announces-second-quarter-200100723</link>
<guid isPermaLink="true">https://6ix.com/company/atara-biotherapeutics-inc/news/atara-biotherapeutics-announces-second-quarter-200100723</guid>
<pubDate>Mon, 11 Aug 2025 20:01:00 GMT</pubDate>
<description>THOUSAND OAKS, Calif., August 11, 2025--Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, today reported financial results for the second quarter 2025 and business updates.</description>
</item>
<item>
<title>Atara Biotherapeutics Announces U.S. FDA Acceptance and Priority Review of the Biologics License Application for Tabelecleucel (Tab-cel®) for the Treatment of Epstein-Barr Virus Positive Post-Transplant Lymphoproliferative Disease</title>
<link>https://6ix.com/company/atara-biotherapeutics-inc/news/atara-biotherapeutics-announces-u-fda-120000453</link>
<guid isPermaLink="true">https://6ix.com/company/atara-biotherapeutics-inc/news/atara-biotherapeutics-announces-u-fda-120000453</guid>
<pubDate>Thu, 24 Jul 2025 12:00:00 GMT</pubDate>
<description>THOUSAND OAKS, Calif., July 24, 2025--Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, today announced that the U.S. Food and Drug Administration (FDA) has accepted the filing of its Biologics License Application (BLA) for tabelecleucel (tab-cel®) indicated as monotherapy for treatment of adult and pediatric pa</description>
</item>
<item>
<title>Perre Fabre Pharmaceuticals, Inc. Announces Transfer of Investigational New Drug Application for Tabelecleucel from Atara Biotherapeutics, Inc.</title>
<link>https://6ix.com/company/atara-biotherapeutics-inc/news/perre-fabre-pharmaceuticals-inc-announces-transfer-of-investigational-new-drug-application-for-tabelecleucel-from-atara-biotherapeutics-inc</link>
<guid isPermaLink="true">https://6ix.com/company/atara-biotherapeutics-inc/news/perre-fabre-pharmaceuticals-inc-announces-transfer-of-investigational-new-drug-application-for-tabelecleucel-from-atara-biotherapeutics-inc</guid>
<pubDate>Tue, 15 Jul 2025 12:00:00 GMT</pubDate>
<description>Pierre Fabre Pharmaceuticals, Inc. today announced the transfer of the Investigational New Drug Application for tabelecleucel from its partner, Atara Biotherapeutics, Inc. (Nasdaq: ATRA). "This announcement marks an important milestone as Pierre Fabre Laboratories assumes global responsibility for clinical development of tabelecleucel following transfer of manufacturing responsibilities earlier in the year," said Adriana Herrera, Chief Executive Officer of Pierre Fabre Pharmaceuticals., the Pier</description>
</item>
<item>
<title>Atara Biotherapeutics Provides Regulatory and Business Updates on Tabelecleucel (Tab-cel®)</title>
<link>https://6ix.com/company/atara-biotherapeutics-inc/news/atara-biotherapeutics-provides-regulatory-business-120000726</link>
<guid isPermaLink="true">https://6ix.com/company/atara-biotherapeutics-inc/news/atara-biotherapeutics-provides-regulatory-business-120000726</guid>
<pubDate>Mon, 14 Jul 2025 12:00:00 GMT</pubDate>
<description>THOUSAND OAKS, Calif., July 14, 2025--Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, today announced that it has resubmitted a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for tabelecleucel (EBVALLO™ or tab-cel®) indicated as monotherapy for treatment of adult and pediatr</description>
</item>
<item>
<title>Atara Biotherapeutics Appoints James Huang and Nachi Subramanian to Board of Directors</title>
<link>https://6ix.com/company/atara-biotherapeutics-inc/news/atara-biotherapeutics-appoints-james-huang-005000269</link>
<guid isPermaLink="true">https://6ix.com/company/atara-biotherapeutics-inc/news/atara-biotherapeutics-appoints-james-huang-005000269</guid>
<pubDate>Sat, 17 May 2025 00:50:00 GMT</pubDate>
<description>THOUSAND OAKS, Calif., May 17, 2025--Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, announced the appointment of James Huang and Nachi Subramanian to its Board of Directors, effective following the completion the Company’s previously announced $16 million offering that was announced on May 15, 2025. The offer</description>
</item>
<item>
<title>Atara Biotherapeutics Announces First Quarter Financial Results and Operational Progress</title>
<link>https://6ix.com/company/atara-biotherapeutics-inc/news/atara-biotherapeutics-announces-first-quarter-123500074</link>
<guid isPermaLink="true">https://6ix.com/company/atara-biotherapeutics-inc/news/atara-biotherapeutics-announces-first-quarter-123500074</guid>
<pubDate>Thu, 15 May 2025 12:35:00 GMT</pubDate>
<description>THOUSAND OAKS, Calif., May 15, 2025--Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, today reported financial results for the first quarter 2025 and business updates.</description>
</item>
<item>
<title>Atara Biotherapeutics Announces Pricing of $16 Million Offering</title>
<link>https://6ix.com/company/atara-biotherapeutics-inc/news/atara-biotherapeutics-announces-pricing-16-123000299</link>
<guid isPermaLink="true">https://6ix.com/company/atara-biotherapeutics-inc/news/atara-biotherapeutics-announces-pricing-16-123000299</guid>
<pubDate>Thu, 15 May 2025 12:30:00 GMT</pubDate>
<description>THOUSAND OAKS, Calif., May 15, 2025--Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, today announced the pricing of an offering of 834,237 shares of its common stock at an offering price of $6.61 per share and pre-funded warrants to purchase 1,587,108 shares of its common stock at an offering price of $6.6099</description>
</item>
<item>
<title>Atara Biotherapeutics Provides Regulatory Updates on EBVALLO™ (tabelecleucel)</title>
<link>https://6ix.com/company/atara-biotherapeutics-inc/news/atara-biotherapeutics-provides-regulatory-updates-210600490</link>
<guid isPermaLink="true">https://6ix.com/company/atara-biotherapeutics-inc/news/atara-biotherapeutics-provides-regulatory-updates-210600490</guid>
<pubDate>Mon, 05 May 2025 21:06:00 GMT</pubDate>
<description>THOUSAND OAKS, Calif., May 05, 2025--Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, today announced that the U.S. Food and Drug Administration (FDA) has lifted the clinical hold on Atara’s active Investigational New Drug (IND) applications for the EBVALLO™ (tabelecleucel) program.</description>
</item>
<item>
<title>Atara Biotherapeutics Announces Fourth Quarter and Full Year 2024 Financial Results and Operational Progress</title>
<link>https://6ix.com/company/atara-biotherapeutics-inc/news/atara-biotherapeutics-announces-fourth-quarter-210100019</link>
<guid isPermaLink="true">https://6ix.com/company/atara-biotherapeutics-inc/news/atara-biotherapeutics-announces-fourth-quarter-210100019</guid>
<pubDate>Fri, 07 Mar 2025 21:01:00 GMT</pubDate>
<description>THOUSAND OAKS, Calif., March 07, 2025--Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, today reported financial results for the fourth quarter and full year 2024, business updates, and key upcoming milestones for 2025.</description>
</item>
<item>
<title>Atara Biotherapeutics Provides Update on Clinical Programs Related to EBVALLO™ (tabelecleucel) and ATA3219</title>
<link>https://6ix.com/company/atara-biotherapeutics-inc/news/atara-biotherapeutics-provides-update-on-clinical-programs-related-to-ebvallotm-tabelecleucel-and-ata3219</link>
<guid isPermaLink="true">https://6ix.com/company/atara-biotherapeutics-inc/news/atara-biotherapeutics-provides-update-on-clinical-programs-related-to-ebvallotm-tabelecleucel-and-ata3219</guid>
<pubDate>Tue, 21 Jan 2025 05:00:00 GMT</pubDate>
<description>U.S. FDA issues clinical hold on EBVALLO™ (tabelecleucel) and ATA3219 studies linked to EBVALLO Complete Response Letter (CRL) THOUSAND OAKS,</description>
</item>
<item>
<title>Atara Biotherapeutics Provides Regulatory and Business Update on EBVALLOTM (tabelecleucel)</title>
<link>https://6ix.com/company/atara-biotherapeutics-inc/news/atara-biotherapeutics-provides-regulatory-and-business-update-on-ebvallotm-tabelecleucel</link>
<guid isPermaLink="true">https://6ix.com/company/atara-biotherapeutics-inc/news/atara-biotherapeutics-provides-regulatory-and-business-update-on-ebvallotm-tabelecleucel</guid>
<pubDate>Thu, 16 Jan 2025 05:00:00 GMT</pubDate>
<description>Atara received FDA Complete Response Letter (CRL) solely related to inspection findings at third-party manufacturer CRL did not identify deficiencies related</description>
</item>
<item>
<title>Atara Biotherapeutics Announces Third Quarter 2024 Financial Results and Operational Progress</title>
<link>https://6ix.com/company/atara-biotherapeutics-inc/news/atara-biotherapeutics-announces-third-quarter-2024-financial-results-and-operational-progress</link>
<guid isPermaLink="true">https://6ix.com/company/atara-biotherapeutics-inc/news/atara-biotherapeutics-announces-third-quarter-2024-financial-results-and-operational-progress</guid>
<pubDate>Tue, 12 Nov 2024 05:00:00 GMT</pubDate>
<description>Tab-cel® U.S. BLA On-Track With PDUFA Target Action Date of January 15, 2025 First Patient Dosed for ATA3219 Non-Hodgkin’s Lymphoma Study; Initial Clinical</description>
</item>
<item>
<title>Atara Biotherapeutics to Announce Third Quarter 2024 Financial Results on Tuesday, November 12, 2024</title>
<link>https://6ix.com/company/atara-biotherapeutics-inc/news/atara-biotherapeutics-to-announce-third-quarter-2024-financial-results-on-tuesday-november-12-2024</link>
<guid isPermaLink="true">https://6ix.com/company/atara-biotherapeutics-inc/news/atara-biotherapeutics-to-announce-third-quarter-2024-financial-results-on-tuesday-november-12-2024</guid>
<pubDate>Tue, 05 Nov 2024 05:00:00 GMT</pubDate>
<description>THOUSAND OAKS, Calif.--(BUSINESS WIRE)-- Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic</description>
</item>
</channel>
</rss>